Robin Rudd

3.7k total citations
50 papers, 2.4k citations indexed

About

Robin Rudd is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, Robin Rudd has authored 50 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Pulmonary and Respiratory Medicine, 18 papers in Oncology and 6 papers in Epidemiology. Recurrent topics in Robin Rudd's work include Occupational and environmental lung diseases (19 papers), Pleural and Pulmonary Diseases (15 papers) and Lung Cancer Research Studies (15 papers). Robin Rudd is often cited by papers focused on Occupational and environmental lung diseases (19 papers), Pleural and Pulmonary Diseases (15 papers) and Lung Cancer Research Studies (15 papers). Robin Rudd collaborates with scholars based in United Kingdom, United States and Ireland. Robin Rudd's co-authors include Stephen Spiro, Gene Colice, M. Beckles, Jeremy Steele, Dean A. Fennell, Jonathan Shamash, Nicole H. Gower, Marie T. Evans, Siow Ming Lee and Michael Sheaff and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Robin Rudd

49 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robin Rudd United Kingdom 22 1.6k 930 476 428 176 50 2.4k
R.M. Rudd United Kingdom 27 2.0k 1.3× 1.1k 1.1× 336 0.7× 470 1.1× 58 0.3× 70 2.8k
Laurent Greillier France 28 1.8k 1.1× 1.6k 1.8× 338 0.7× 530 1.2× 83 0.5× 206 3.0k
Hiroshi Kagamu Japan 27 1.0k 0.6× 1.6k 1.7× 299 0.6× 534 1.2× 38 0.2× 172 3.0k
A Mussi Italy 26 1.2k 0.7× 956 1.0× 174 0.4× 1.1k 2.5× 94 0.5× 61 2.5k
Nobukazu Fujimoto Japan 27 1.3k 0.8× 773 0.8× 104 0.2× 659 1.5× 107 0.6× 133 2.3k
Sun Min Lim South Korea 27 1.6k 1.0× 1.5k 1.6× 229 0.5× 900 2.1× 41 0.2× 132 2.8k
Nader Hanna United States 30 736 0.5× 1.5k 1.6× 233 0.5× 804 1.9× 91 0.5× 111 3.0k
Brett Hughes Australia 31 2.1k 1.3× 2.3k 2.5× 639 1.3× 820 1.9× 79 0.4× 179 4.4k
Norio Mitsuhashi Japan 28 1.4k 0.9× 583 0.6× 227 0.5× 388 0.9× 40 0.2× 188 2.8k
Sculier Jp Belgium 21 1.6k 1.0× 1.1k 1.2× 200 0.4× 819 1.9× 21 0.1× 60 2.7k

Countries citing papers authored by Robin Rudd

Since Specialization
Citations

This map shows the geographic impact of Robin Rudd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin Rudd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin Rudd more than expected).

Fields of papers citing papers by Robin Rudd

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robin Rudd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin Rudd. The network helps show where Robin Rudd may publish in the future.

Co-authorship network of co-authors of Robin Rudd

This figure shows the co-authorship network connecting the top 25 collaborators of Robin Rudd. A scholar is included among the top collaborators of Robin Rudd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robin Rudd. Robin Rudd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fennell, Dean A., J.F. Lester, Sarah Danson, et al.. (2022). Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial. EClinicalMedicine. 48. 101432–101432. 17 indexed citations
2.
Lee, Siow Ming, Sunil Upadhyay, C. Lewanski, et al.. (2019). The clinical role of VeriStrat testing in patients with advanced non–small cell lung cancer considered unfit for first-line platinum-based chemotherapy. European Journal of Cancer. 120. 86–96. 5 indexed citations
3.
Lee, Siow Ming, Iftekhar Khan, Sunil Upadhyay, et al.. (2012). First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 13(11). 1161–1170. 133 indexed citations
4.
Lee, Siow Ming, Penella J. Woll, Robin Rudd, et al.. (2009). Anti-angiogenic Therapy Using Thalidomide Combined With Chemotherapy in Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial. JNCI Journal of the National Cancer Institute. 101(15). 1049–1057. 95 indexed citations
5.
Lee, Siow Ming, Robin Rudd, Penella J. Woll, et al.. (2009). Randomized Double-Blind Placebo-Controlled Trial of Thalidomide in Combination With Gemcitabine and Carboplatin in Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 27(31). 5248–5254. 50 indexed citations
6.
Stebbing, Justin, Thomas Powles, Kirsty McPherson, et al.. (2008). The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer. 63(1). 94–97. 108 indexed citations
7.
8.
Fennell, Dean A., Jeremy Steele, Jonathan Shamash, et al.. (2006). Efficacy and safety of first‐ or second‐line irinotecan, cisplatin, and mitomycin in mesothelioma. Cancer. 109(1). 93–99. 37 indexed citations
9.
Rudd, Robin, et al.. (2006). Gemcitabine and carboplatin: is this the best combination for non-small cell lung cancer?. Expert Review of Anticancer Therapy. 6(2). 165–173. 6 indexed citations
10.
Milroy, Robert, Nicole H. Gower, Mahesh Parmar, et al.. (2005). A randomised comparison of radical radiotherapy with or without chemotherapy for patients with non-small cell lung cancer: Results from the Big Lung Trial. Radiotherapy and Oncology. 75(2). 134–140. 4 indexed citations
11.
Steele, Jeremy, Astero Klabatsa, Dean A. Fennell, et al.. (2005). Prognostic factors in mesothelioma. Lung Cancer. 49. S49–S52. 48 indexed citations
12.
Fennell, Dean A. & Robin Rudd. (2004). Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development. The Lancet Oncology. 5(6). 354–362. 66 indexed citations
13.
Fennell, Dean A., Jeremy Steele, Jonathan Shamash, et al.. (2004). Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma. Lung Cancer. 47(2). 277–281. 40 indexed citations
14.
Fennell, Dean A. & Robin Rudd. (2004). Pulmonary toxicity and cancer treatment. Hospital Medicine. 65(8). 462–465. 1 indexed citations
15.
Beckles, M., Stephen Spiro, Gene Colice, & Robin Rudd. (2003). The Physiologic Evaluation of Patients With Lung Cancer Being Considered for Resectional Surgery*. CHEST Journal. 123(1). 105S–114S. 237 indexed citations
16.
Beckles, M., Stephen Spiro, Gene Colice, & Robin Rudd. (2003). Initial Evaluation of the Patient With Lung Cancer*. CHEST Journal. 123(1). 97S–104S. 142 indexed citations
17.
Ashman, Neil, Jeremy Steele, M. Sheaff, Robin Rudd, & James K. Onwubalili. (2000). Membranous nephropathy resolving with treatment of bronchial carcinoid tumor. American Journal of Kidney Diseases. 36(3). e15.1–e15.4. 17 indexed citations
18.
Souhami, Robert L., et al.. (1992). Phase II study of Edatrexate in stage III and IV non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology. 30(6). 465–468. 30 indexed citations
19.
Currie, D C, David Miles, Robin Rudd, et al.. (1990). Mitomycin, ifosfamide and cisplatin in non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology. 25(5). 380–381. 21 indexed citations
20.
Rudd, Robin, et al.. (1983). Inhibition of exercise-induced asthma by an orally absorbed mast cell stabilizer (M & B 22,948). British Journal of Diseases of the Chest. 77(1). 78–86. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R.M. Rudd Breakdown of academic impact, for papers by Laurent Greillier Breakdown of academic impact, for papers by Hiroshi Kagamu Breakdown of academic impact, for papers by A Mussi Breakdown of academic impact, for papers by Nobukazu Fujimoto Breakdown of academic impact, for papers by Sun Min Lim Breakdown of academic impact, for papers by Nader Hanna Breakdown of academic impact, for papers by Brett Hughes Breakdown of academic impact, for papers by Norio Mitsuhashi Breakdown of academic impact, for papers by Sculier Jp
Rankless by CCL
2026